Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab maintenance after chemoradiotherapy for bladder preservation in muscle-invasive bladder cancer
2018-001807-35Phase 2Active
- Sponsor
- Unicancer
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in muscle-invasive bladder cancer (MIBC), sponsored by Unicancer. Primary endpoint: Disease-free survival. Started Aug 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2018-001807-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001807-35.